Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Volitinib plus Gefitinib in EGFR-mutated NSCLC
NCT02374645Phase 1Completed
- Sponsor
- Hutchison MediPharma (HMP)
- Start
- Apr 2015
- Primary completion
- Feb 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of savolitinib in non-small cell lung cancer (NSCLC) (2 arms), sponsored by Hutchison MediPharma (HMP). Primary endpoint: Number of adverse events and serious adverse events. Started Apr 2015; status: completed.
02
Drugs
savolitinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT02374645.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02374645.